Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population

Muscle and Nerve

Volumn 46, Issue 4, 2012, Pages 496-505

  Furst, Daniel E ^a   Amato, Anthony A ^b   Iorga, Şerban R ^c   Bancroft, Tim ^c   Fernandes, Ancilla W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c OPTUM   (United States)

^d MEDIMMUNE   (United States)

Author keywords

Costs; Database; Inflammatory myopathy; Myositis; Resources; Retrospective

Indexed keywords

ADULT; AGED; AMBULATORY CARE; ANALYSIS; ARTICLE; CONTROLLED STUDY; DATA BASE; DERMATOMYOSITIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; MYOSITIS; YOUNG ADULT;

EID: 84866325704     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23384     Document Type: Article

References (24)

1. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80: 1060-1068.
2. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80: 1186-1193.
3. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-a/b mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-678.
4. Pongratz D, Spath M, Fischer P. Myositis as a cause of muscle pain. J Musculoskel Pain 1999; 7: 121-129.
5. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 161-170.
6. Hengstman G, van den Hoogen F. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009; 10: 1183-1190.
7. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982.
8. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35: 445-447.
9. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48: 715-723.
10. Prieto S, Grau JM. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010; 9: A330-334.
11. Bendewald MJ, Wetter DA, Li X, Davis M. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol 2010; 146: 26-30.
12. Furst DE, Amato AA, Iorga ŞR, Gajria K, Fernandes AW. Epidemiology of idiopathic inflammatory myopathy in a U.S. managed care plan. Muscle Nerve (in press).
13. Gupta SJ. The idiopathic inflammatory myopathies: current perspectives and management. J Indian Rheumatol Assoc 2004; 12: 58-69.
14. Lundberg I, Chung Y. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (Oxford) 2000; 39: 7-17.
15. Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995; 38: 1218-1224.
16. Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003; 24( suppl): S256-259.
17. Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 2009; 15: 338-40.
18. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010; 13: 618-625.
19. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
20. Bernatsky S, Panopalis P, Pineau CA, Hudson M, St Pierre Y, Clarke AE. Healthcare costs of inflammatory myopathies. J Rheumatol 2011; 38: 885-888.
21. Trading Economics USDCAD-Canadian dollar exchange rate. Available at: http://www.tradingeconomics.com/canada/currency [accessed January 2, 2012].
22. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009; 51: 66-79.
23. Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997; 27: 73-84.
24. Amato AA, Griggs RC. Dragons, unicorns, polymyositis, and other mythological beasts. Neurology 2003; 61: 288-290.